Skip to content

Cranberry (PACs)

Also called Cranberry Supplements

The original UTI supplement.

  • CategoryImmune & Detox
  • FormProanthocyanidin-standardized extract
  • EvidenceClinical trials on file

Where to get Cranberry (PACs)

iHerb
Proanthocyanidin-standardized extract

Cam’s partner link opens iHerb on this product. No code needed; the link credits Cam.

Shop on iHerb

The short version

  • What it doesCranberry does not kill anything, and the whole page follows from that. Its proposed action is anti-adhesion: A-type proanthocyanidins interfere with the P-fimbriae that uropathogenic Escherichia coli use to attach to the bladder wall.
  • Who it is forWomen with recurrent UTIs. Prevention only.
  • What to watchGI upset, and the sugar load if you use juice rather than an extract.

How Cranberry (PACs) works

Type-A proanthocyanidins prevent E. coli P-fimbriae from adhering to the urothelium — the bacteria are then flushed rather than killed, so there is no selection pressure for resistance. The type-A linkage is essential; the type-B proanthocyanidins in most other fruits do not do this.

Cranberry (PACs): serving, timing and spacing

Suggested serving
36 mg PACs daily is the commonly cited threshold. Read the PAC content, not the milligrams of 'cranberry'.
How often
Daily
When
Any time; PAC content is what matters, not juice volume

General referenceA general reference intake for education, not a prescription. The label on the product you buy is the final word.

Good to know

Buy on PAC content or do not bother — a 500 mg cranberry capsule with unstated PACs is a lottery ticket. Cranberry juice is mostly sugar and will not reach the dose. It does NOT treat an active UTI; that needs antibiotics.

Research on Cranberry (PACs)5 evidence notes: clinical, correlative, theoretical

Each note sits under the kind of evidence it stands on. A thin or missing trial means nobody has run it yet, not that it doesn’t work. How the evidence tiers work

Human clinical evidence

  • The 2023 Cochrane review — 50 trials, ~9,000 participants — concluded cranberry products DO reduce recurrent UTI risk in women with recurrent UTI, in children, and after urological interventions.

  • It found no benefit in elderly institutionalized populations, pregnancy or bladder-emptying disorders.

  • The earlier negative trials largely used juice or low-PAC products, which is the most likely explanation for the inconsistency.

Correlative data

  • Traditional use by Indigenous peoples of North America and a long-standing folk association with urinary health in settler populations. Cohort data supports the association for recurrence; the trials are the weaker half, largely because juice contains too little PAC to work.

Theoretical / extrapolated benefits

  • Type-A proanthocyanidins block E. coli P-fimbriae adhesion to the urothelium. It prevents attachment; it does not treat an established infection.

Sources read for this page

  • Babar A. High dose versus low dose standardized cranberry proanthocyanidin extract for the prevention of recurrent urinary tract infection in healthy women: a double-blind randomized controlled trial. BMC Urol 2021 · PMID 33757474
  • Howell AB. Differences in Urinary Bacterial Anti-Adhesion Activity after Intake of Cranberry Dietary Supplements with Soluble versus Insoluble Proanthocyanidins. J Diet Suppl 2022 · PMID 33818241
  • Moro C. Cranberry Juice, Cranberry Tablets, or Liquid Therapies for Urinary Tract Infection: A Systematic Review and Network Meta-analysis. Eur Urol Focus 2024 · PMID 39030132
  • Xiong Z. Preventive effect of cranberries with high dose of proanthocyanidins on urinary tract infections: a meta-analysis and systematic review. Front Nutr 2024 · PMID 39668896
  • Howell AB. Differences in P-Type and Type 1 Uropathogenic Escherichia coli Urinary Anti-Adhesion Activity of Cranberry Fruit Juice Dry Extract Product and D-Mannose Dietary Supplement. J Diet Suppl 2024 · PMID 38804849
  • Xu J. Cranberry Research Progress: A Systematic Review of Chemical Composition, Pharmacological Mechanisms, Clinical Applications, and Nutritional Significance. Int J Mol Sci 2025 · PMID 41096972

Cranberry (PACs), the deep readThe mechanism, cell to human, which form, how you would know

What Cranberry (PACs) actually does

Cranberry does not kill anything, and the whole page follows from that. Its proposed action is anti-adhesion: A-type proanthocyanidins interfere with the P-fimbriae that uropathogenic Escherichia coli use to attach to the bladder wall. A bacterium that cannot attach is washed out at the next void. This is a mechanical claim rather than an antimicrobial one, which is why nobody reports a minimum inhibitory concentration for cranberry and why a susceptibility panel would not show anything Xu 2025.

The A-type linkage is the specification, not the proanthocyanidin. Proanthocyanidins are flavan-3-ol oligomers, and most plants make B-type ones, joined by a single carbon-carbon bond. Cranberry makes A-type oligomers carrying an additional ether bond between the units, which locks the shape. Grape seed, pine bark and cocoa are rich in proanthocyanidins and poor in A-type linkages, and they do not carry this claim. A label that says “proanthocyanidins” without saying A-type has told you the class and withheld the specification.

There are two adhesins and they are not the same target. P-fimbriae end in the PapG adhesin, which binds galabiose disaccharide on uroepithelial cells and is the pyelonephritis-associated system. Type 1 fimbriae end in FimH, which binds mannosylated uroplakin and is the system D-mannose competes with. A head-to-head comparison found a cranberry juice dry extract and a D-mannose supplement produced different urinary anti-adhesion activity against the two fimbrial types Howell 2024. They are complements, not substitutes, and no product label explains that.

The read-out that makes this measurable is urinary, not plasma. Proanthocyanidin oligomers above about 2 units are poorly absorbed intact; what appears in urine is a mixture of small metabolites and microbially derived phenolics. So the meaningful assay collects a volunteer's urine after a dose and tests whether that urine blocks bacterial agglutination ex vivo. Anti-adhesion activity measured that way differs between products taken at the same milligram dose Howell 2022, which is a fact about manufacturing rather than about botany.

And it is prevention, by construction. An anti-adhesion agent acts on planktonic bacteria arriving at an unoccupied surface. It has no mechanism against an established infection, an intracellular bacterial community or a catheter biofilm, and no part of the mechanistic literature claims otherwise Xu 2025.

Cell, rodent, human — and where it stops

Cell to human is unusually short here, because the assay is already a human assay. The chain runs from bacterial agglutination in a plate, to a person's urine tested in that same plate, to a randomized trial counting infections. All three steps exist. The problem is that the third step keeps disagreeing with the second.

The dose-ranging trial is the one that should be famous and is not. Healthy women with recurrent urinary tract infection were randomized to a high dose of standardized proanthocyanidin extract, 2 doses of 18.5 mg daily in 72 women, or a control low dose of 2 doses of 1 mg daily in 73 women, for 24 weeks. The high dose was not associated with a reduction in symptomatic infections against the low dose Babar 2021. An 18-fold difference in the active compound produced no measurable difference in outcome, which is a hard result for a dose-response story to absorb.

The meta-analytic picture is more favorable and it is doing something subtly different. Pooled analysis restricted to high-proanthocyanidin cranberry preparations reports a preventive effect on urinary tract infections Xiong 2024, and a network meta-analysis separating juice from tablets from other liquid therapies finds the formats do not perform identically Moro 2024. Pooling across products with a dose threshold is not the same experiment as randomizing 1 product to 2 doses, and when those 2 designs disagree the honest reading is that the effect, if it exists, is smaller than the between-product variation.

The obstacle to transfer is that the population in the trials is narrow. Almost all of this evidence is in women with recurrent uncomplicated cystitis. It does not extend to men, to catheterized patients, to people with structural urinary tract abnormalities, or to treating an infection that has already started, and pretending otherwise is how a prevention product ends up delaying antibiotics.

What travels best is the ex vivo signal. Urine from people taking a juice-derived extract shows different bacterial anti-adhesion activity from urine of people taking a whole-berry powder at the same stated dose Howell 2022. That is a within-person, product-level measurement and it is the strongest reason to believe the form question below is real.

Cranberry (PACs) — which form, and does it matter

The first form question is soluble versus insoluble proanthocyanidins, and it is the finding that should change what people buy. Proanthocyanidins in whole-berry powder are substantially bound to cell-wall material and are not extracted the way the soluble fraction of a juice-derived extract is. When both were taken once daily, the juice extract product produced significantly higher urinary anti-adhesion activity than the blended whole-berry product Howell 2022. Two labels can declare the same 36 mg of proanthocyanidins and deliver different amounts of the thing that acts.

The second is that the 36 mg number is method-dependent. Proanthocyanidin content in these products is quantified by the 4-dimethylaminocinnamaldehyde colorimetric assay against a procyanidin A2 standard. Change the standard, the extraction solvent or the assay and the same material reports a different number. A milligram figure with no method named beside it is not comparable to another milligram figure with no method named beside it, and both appear on shelves as if they were Xu 2025.

The third is format, and the network meta-analysis says it matters. Juice, tablets and other liquid preparations were separated in a systematic review and network meta-analysis rather than pooled Moro 2024. Juice carries a sugar load and a volume that itself increases urine flow, which is a confounded comparator: part of what juice does is make people drink. A tablet isolates the chemistry and loses the fluid.

The fourth is that cranberry and D-mannose are sold interchangeably and target different fimbriae. The measured urinary anti-adhesion profiles against P-type and type 1 Escherichia coli differ between a cranberry juice dry extract and a D-mannose supplement Howell 2024. Someone whose recurrent isolates are type 1 fimbriated has bought the wrong bottle, and no clinical pathway currently types them.

And the label word to distrust is “cranberry 500 mg”. That number is the mass of powder. Without a declared proanthocyanidin content by a named method, the concentration of the only compound class with a mechanism is unknown, and 500 mg of a weak powder is a smaller dose than 100 mg of a standardized extract.

What would have to be true, and how you would know it was not

1. The clean falsifiable prediction, at 6 months. In a woman with 3 or more culture-confirmed infections a year, count symptomatic episodes for 6 months before and 6 months during a standardized high-proanthocyanidin extract. Prediction from the pooled data is a reduction Xiong 2024; prediction from the only dose-ranging trial is no difference Babar 2021. Those 2 predictions conflict, which is exactly why an individual record is worth keeping rather than trusting either.

2. Predict the urine culture, not the symptom. Dysuria and urgency have many causes and a supplement gets credit for all of them. The honest endpoint is a culture at the time of symptoms, because a negative culture during a symptomatic episode means the product did not fail; it means the episode was not a urinary tract infection.

3. The mechanism-level prediction anybody with a laboratory could run. Collect urine 6 hours after a dose and test it for bacterial anti-adhesion activity against a P-fimbriated strain. Prediction: a juice-derived extract raises it and an equivalent milligram dose of whole-berry powder raises it less Howell 2022. This is the assay that would let a vendor prove its product works, and almost none of them publish it.

4. Predict no effect on an active infection, within 48 hours. If somebody with an established, culture-positive infection takes cranberry instead of antibiotics, the prediction is that the culture stays positive and the illness progresses. This is the prediction with consequences, and it is the reason the mechanism section says the word prevention.

5. The prediction that would embarrass the format. Compare cranberry juice against the same volume of water in people who otherwise drink little. If the water arm performs as well, most of what juice does is hydration and dilution rather than anti-adhesion Moro 2024. Predict a smaller gap than the juice literature implies, and note that this trivially cheap comparison is not in the network.

What nobody has tested yet

Nobody has reconciled the dose-ranging trial with the meta-analyses. One randomized comparison of 37 mg against 2 mg of proanthocyanidins daily for 24 weeks found no difference Babar 2021, while pooled analyses restricted to high-proanthocyanidin products find benefit Xiong 2024. Either the dose-response is flat above some low threshold, or product differences swamp dose, or the pooled effect is confounded by which products get studied. Those are 3 testable explanations and no study distinguishes them.

Nobody has typed the bacteria before choosing the supplement. The anti-adhesion profiles against P-type and type 1 strains differ by product Howell 2024, and no trial has stratified participants by the fimbrial type of their own recurrent isolate. That is the trial that would turn this category from a lottery into a match, and it needs nothing that a clinical microbiology laboratory does not already do.

Nobody has standardized the assay across the market. The colorimetric method for proanthocyanidin content has known standard-dependence, and there is no published survey buying 20 on-market products and reporting content by 2 methods side by side Xu 2025. Until that exists, cross-product dose comparison is not possible.

And nobody has tested the combination. Cranberry plus D-mannose is sold as a single capsule and has never been compared against either alone on infection counts, despite a clear mechanistic rationale for additivity Howell 2024.

Cranberry (PACs) — its own safety story, not its category's

The interaction people worry about is warfarin, and the honest position is that it is unresolved rather than dismissed. Case reports of raised international normalized ratio on cranberry juice prompted regulatory advisories; controlled pharmacokinetic studies have largely failed to reproduce a consistent effect. The practical answer is neither to panic nor to ignore it: anyone on warfarin who starts or stops cranberry should have an international normalized ratio checked within 1 to 2 weeks, which costs nothing and settles it for that person.

Oxalate is the risk that is specific to this fruit. Cranberry is a meaningful dietary oxalate source and concentrated extracts concentrate it. For a person with calcium oxalate stone disease, a daily supplement taken for years to prevent 1 urinary problem may contribute to another, and the relevant test is a 24-hour urine oxalate rather than a serum measurement.

The salicylate content is real and usually irrelevant. Cranberry contains salicylic acid and regular juice intake measurably raises urinary salicylate. This matters only for people with a genuine salicylate sensitivity, and it is worth knowing rather than worth worrying about.

Sugar is the safety issue on the format nobody flags. The cranberry juice cocktail that most people mean when they say cranberry juice is sweetened, and drinking a glass daily for prevention adds a carbohydrate load every day for years. In anyone managing glycemia this is not a footnote, and it is a reason the tablet and the juice are different products in more ways than the network meta-analysis measured Moro 2024.

The dangerous failure mode is delay. Fever, flank pain, vomiting or blood in the urine are signs that an infection may have reached the kidney, and an anti-adhesion agent has no mechanism against that Xu 2025. Nothing on this page is medical advice or a diagnosis, and a suspected urinary tract infection needs a clinician and a culture rather than a larger dose.

Cranberry (PACs) safety basics4 points of its own

Its own safety story

  • GI upset, and the sugar load if you use juice rather than an extract.
  • Interacts with warfarin — case reports of raised INR and bleeding. The mechanism is disputed but the reports are consistent enough to matter.
  • High in oxalate — a real kidney stone risk with sustained high intake, which is awkward given it is taken for urinary health.
  • It does not treat an established UTI. A UTI that is not improving needs antibiotics, and delay risks a kidney infection.

Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor. Pharmacists are underused and free.

Bloodwork to run4 tests in one order, code CAMERON

The effect itself has no blood test. That is a fact about the effect, and it changes how you should judge it.

  • What to watchAntibiotic courses per year, and doctor-confirmed infections rather than remembered ones. That count is the endpoint behind the 2023 Cochrane conclusion that cranberry prevents recurrence in women who get recurrent UTIs, and your own pharmacy record can give you the years before you started.
  • How long before it means anythingSix to twelve months. Recurrence is a rate and rates need a calendar — a quiet eight weeks is the normal gap between infections for a lot of people, not a result.
  • What will fool youThe dose of the one molecule that matters. The negative trials largely used juice or capsules carrying too little proanthocyanidin, so a bottle that will not print its PAC content is a lottery ticket and a null result tested the bottle rather than the berry. The other trap is treating this as a treatment: it blocks attachment and does nothing to an infection already established. Burning, fever, back pain or blood means antibiotics and a doctor today.

The labs mapped to Cranberry (PACs)

4 tests in one order
Marek Diagnostics · no doctor’s visit
Code CAMERON
Order these 4 tests

Code CAMERON applies automatically at checkout. Draw before you start, not after: a result with nothing to compare it to answers nothing.

The Frequent Illness & Immune Resilience panel, explained

Cranberry (PACs) FAQ5 common questions

What is Cranberry (PACs)?
The original UTI supplement. The evidence went from positive to negative to positive again, and where it landed depends entirely on the dose of one specific molecule.
What is the suggested dose of Cranberry (PACs)?
36 mg PACs daily is the commonly cited threshold. Read the PAC content, not the milligrams of 'cranberry'. This is a general reference for education only. Statements have not been evaluated by the FDA and this is not medical advice.
Who is Cranberry (PACs) for?
Women with recurrent UTIs. Prevention only.
Which labs show whether Cranberry (PACs) is doing anything?
Complete Blood Count (CBC) with Differential, Vitamin D (25-Hydroxy), Zinc, Plasma, Comprehensive Metabolic Panel (CMP). Draw a baseline before you start, then recheck.
Where can I buy Cranberry (PACs)?
Coach Cam sources Cranberry (PACs) from vetted, top-rated brands on iHerb. Use the buy link on this page.
The Before-You-Stack Lab Kit cover

The free Before‑You‑Stack Lab Kit

The 12 labs I’d run before any protocol, what each one tells you, add-ons by goal and how to order them yourself. The PDF is yours straight away.

After that it is about two emails a week: a marker, a compound or a protocol. Unsubscribe in one click.

The full stack plan is inside Skool

This page covers what Cranberry (PACs) is, what the research says and how people take it. Skool puts it in order alongside everything else you run, peptides included.

Free on this page

What Cranberry (PACs) is and how it works · The serving, its basis, and its safety lines · The research and the bloodwork that shows it

  • What Cranberry (PACs) is and how it works
  • The serving, its basis, and its safety lines
  • The research and the bloodwork that shows it

Members get

  • Cranberry (PACs) in your full stack: what it runs with, and what it cancels out
  • How it fits with your peptides: what it pairs with, and what it overlaps
  • The retest plan: Complete Blood Count (CBC) with Differential baseline, the recheck, what a change means
Join Skool $10/mo1,500+ members, 5.0 rating from 15 reviews. Cancel anytime.
The members' Prep Bench in Skool: the compound finder (no dose shown)
The members’ Prep Bench

Want it built around you?

The coaching app, with sample data

1-on-1 coaching with Cam

Your plan, your bloodwork and your check-ins, built around you.

Research Protocol $150/mo · Full Coaching $250/mo

See coaching

One question? Book a 15-minute consult

A call with Cam on the one thing you are stuck on.

$75 per call

Book a consult

Educational reference only. Not medical advice. These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure or prevent any disease. Some links are affiliate links; Cam may earn a commission at no extra cost to you. Medical disclaimer & affiliate disclosure

Buy on iHerbJoin Skool